.Pharmacolibrary.Drugs.N_NervousSystem.N07X_OtherNervousSystemDrugs.N07XX07_Fampridine.Fampridine .Pharmacolibrary.Drugs.N_NervousSystem.N07X_OtherNervousSystemDrugs.N07XX07_Fampridine.Fampridine| name: | Fampridine |
| ATC code: | N07XX07 | route: | oral |
| n-compartments | 1 |
Fampridine (also known as 4-aminopyridine, dalfampridine) is a potassium channel blocker used to improve walking in adults with multiple sclerosis (MS). It is approved and marketed for symptomatic treatment in MS patients to enhance walking speed.
Single-dose pharmacokinetic study in healthy adult volunteers after oral administration.
Weir, S, et al., & Henney, HR (2013). Population pharmacokinetics and pharmacodynamics of dalfampridine-ER in healthy volunteers and in patients with multiple sclerosis. Current medical research and opinion 29(12) 1637–1645. DOI:10.1185/03007995.2012.749222 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23157466
Vollmer, T, et al., & Henney, HR (2009). Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up study. Clinical therapeutics 31(10) 2215–2223. DOI:10.1016/j.clinthera.2009.10.007 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19922892